Phase III Clinical Trial Evaluating the Efficacy and Safety of 5-aminolevulinic Acid (5-ALA）
Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open, parallel-group, multicenter clinical trial evaluating
5-aminolevulinic acid (5-ALA HCl) oral solution with powdered fluorescent microscopic tumor
resection versus white light microscopic tumor resection in patients with malignant gliomas
(WHO grade 3/4).